BALDERTON-CAPITAL
Balderton Capital announces today that it has hired two new General Partners. Rana Yared joins from Goldman Sachs, where she was Partner in the Principal Strategic Investments team. David Thévenon joins from SoftBank’s Vision Fund, where he was one of the initial Partners.
Bernard Liautaud, Managing Partner of Balderton Capital, said: "I am delighted to welcome Rana and David to the partnership. They both bring outstanding experience in investing globally in the technology ecosystem. With her team at Goldman Sachs, Rana has built one of the best fintech and AI portfolios across the US and Europe. And within Softbank, David has participated in the growth journeys of companies as diverse as Didi in China, Grab in Singapore, Lemonade and SoFi in the US. The opportunity in the European tech ecosystem continues to expand at a rapid pace, and Rana and David will play a key role in our investment strategy in the European venture space."
During her time at Goldman Sachs, Rana’s team invested $2bn in 80 companies, with a strong focus on fintech. As one of Goldman’s best-known tech investors, Rana led the US and European Principal Strategic Investment (PSI) teams and served on Goldman’s Growth Equity Investment committee. She spent five years on the board of the fixed income trading platform Tradeweb, until it went public in April 2019 with a market capitalisation of $6bn. Rana also brought the artificial intelligence platform Kensho to Goldman Sachs. Kensho was ultimately sold to S&P Global for $550m in March 2018.
Rana currently sits on the boards of Nutmeg, Vestwell, NAV, Pensando, Digital Reasoning, Veem, and NYSHEX. She joined Goldman Sachs as an analyst in 2006 and was named Managing Director in 2013 and Partner in 2018.
Rana Yared said: “My greatest passion is working closely with founders and their teams to build new companies, and I am delighted to be able to devote myself to this when I join Balderton. In recent years, Europe has established itself as a tech leader and is brimming with potential and opportunity. I am excited to move back to the European side of the Atlantic and to begin seeking out and working with the next generation of exciting tech companies.”
During his five-year tenure at SoftBank, David led investments in Didi Chuxing, the world's leading mobile transportation platform; Grab, Southeast Asia's leading superapp; Ola, India's leading ride-sharing platform; Lemonade, the digital insurance company powered by AI and driven by social good; SoFi, the American online personal finance platform; and Kabbage, one of the leading US SMB lending platforms. David was also involved in SoftBank's investments in 99 in Brazil (bought by Didi) and Legendary Pictures in the US (sold to Wanda Group).
Before joining SoftBank, David had a 10-year career at Google, where he worked on partnerships for products that touched billions of users, including leading global product and business partnerships for Google's Android platform.
David Thévenon said: “Five years ago I left Google to focus on venture investing at SoftBank and I felt privileged to meet, invest and work with some of the most innovative and visionary founders, supporting them as they grew into market-leading companies. Joining Balderton will allow me to continue this for European-founded companies, and I am truly excited about the opportunity ahead.”
[ENDS]
About Balderton:
Balderton Capital is a London-based venture firm focused exclusively on backing the best European-founded technology companies. In the two decades since our founding, we have worked with hundreds of extraordinary European founders, and have raised eight funds totalling more than $3bn. Balderton’s most recent funds were the early-stage Balderton VII, raised in November 2019, and Liquidity I, Europe’s first venture fund dedicated to secondary investments in European-founded, growth-stage technology startups, raised in October 2018. Previous exited investments include Betfair (FTSE: BET), Magic Pony (Twitter), NaturalMotion (Zynga), Recorded Future (Insight Partners), Sunrise (Microsoft), Talend (NASDAQ: TLND) and Yoox Net-a-Porter (BIT: YNAP). Among Balderton’s current portfolio of over 90 companies are Aircall, Carwow, Citymapper, Contentful, Darktrace, Depop, GoCardless, The Hut Group, Kobalt Music, Nutmeg, Peakon, Prodigy Finance, Revolut, SOPHiA Genetics, Tessian, Vestiaire Collective, Vivino, Voi Technology, and Zego.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200207005243/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom